Research
Hormonal
GLP-1 receptor agonists exhibit protective effects on the kidneys by reducing the decline in estimated glomerular filtration rate (eGFR) and delaying the onset of proteinuria in patients with Type 2 Diabetes.
GLP-1RAs help protect your kidneys from damage caused by diabetes. They slow down the loss of kidney function and reduce protein leakage into the urine, which is crucial for long-term kidney health.
GoodSupportsHIGH confidence
Several recent CVOTs have shown that GLP-1RAs can reduce the decline of estimated GFR (eGFR) and delay the onset of the occurrence of proteinuria in patients with T2DM [4, 22, 26, 46, 47].
Why this rating
Supported by multiple CVOTs (LEADER, SUSTAIN-6, EXSCEL, AWARD-7).
Source
GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential
Xiaoxuan Ma et al. · International Journal of Biological Sciences · 2021
DOI 10.7150/ijbs.59965
narrative_reviewCited 267×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP-1 receptor agonists (GLP-1RAs) reduce major adverse cardiovascular events (MACE), cardiovascular mortality, and all-cause mortality in patients with type 2 diabetes, particularly those with established cardiovascular disease.Strong
- GLP-1 receptor agonists reduce blood pressure and improve lipid profiles (LDL-C, triglycerides), contributing to the stabilization of atherosclerotic plaques and reduced cardiovascular risk.Good
- GLP-1 receptor agonists may increase the risk of adverse heart failure outcomes in patients with heart failure and reduced left ventricular ejection fraction (LVEF), despite showing cardiovascular benefits in other populations.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →